COVID-19 infection and cancer regression: a review of current evidence, potential mechanisms, and clinical perspectives on a Paradoxical phenomenon.

Since its emergence, the coronavirus (SARS-CoV-2) outbreak has been a pandemic responsible for about 7 million deaths worldwide. Numerous studies have been conducted to determine the virus's multiorgan system involvement, particularly its relation to cancer biology. Spontaneous regression of cancer has been observed in some patients with the coronavirus, which may be attributed to the virus's ability to trigger specific immune responses that can be oncolytic and help reduce and eliminate oncogenic cells. This study aims to explore the paradoxical effects of COVID-19 in inducing cancer regression. The paradoxical effect of SARS-CoV-2 infection has been attributed to the possibility of a heightened immune activation possibly triggered by the virus, and some of these include increased levels of cytokines such as interferon and tumor necrosis factor-alpha (TNF-α), as well as the activation of T cells and natural killer (NK) cells. COVID-19-induced cancer regression presents new perspectives on the relationship between viral infections and the immune system's antitumor capabilities. This would help foster future research investigating specific immune pathways activated during SARS-CoV-2 and discover how these can be therapeutically harnessed to aid cancer regression.